| Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. | |
| | |
MedLine Citation:
|
PMID: 12052629 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The in vitro activity of piperacillin/tazobactam and several comparison broad-spectrum compounds was assessed against recent clinical isolates of Gram-positive and -negative bacteria from geographically diverse medical centers in Europe, North and Latin America participating in various surveillance programs in 2000. Several organisms were characterized for phenotypic expression of various resistant determinants such as extended-spectrum beta-lactamase (ESBL) or amp C cephalosporinase hyperproduction, and vancomycin resistance in enterococci (VRE). Piperacillin/tazobactam retained activity (MIC50) against oxacillin-susceptible Staphylococcus spp. (0.12-0.5 microg/ml), Bacillus spp. (0.5 microg/ml), vancomycin-susceptible enterococci (>4 microg/ml), and Corynebacterium spp. (2 microg/ml; not including C. jeikeium) with susceptibility rates of 100.0, 91.7, 85.7 and 81.8%, respectively. Piperacillin/tazobactam inhibited all Streptococcus spp. strains at < or = 16 microg/ml, including penicillin-resistant strains many of which were co-resistant to erythromycin (90%) and other beta-lactams. A specific breakpoint for these streptococci when testing piperacillin/tazobactam appears needed to prevent false-resistant reports using penicillin as a class representative. The carbapenems among beta-lactams were the most active agents against the ESBL-producing species of Escherichia coli and Klebsiella pneumoniae and those strains which hyper-express amp C enzymes including Citrobacter spp. and Enterobacter spp. Piperacillin/tazobactam only exhibited modest activity against the "amp C resistance group" strains (68.8% susceptible or intermediate, MIC < or = 64 microg/ml). Piperacillin/tazobactam (MIC50, 8 microg/ml; 79.5% susceptible) was the most active agent tested against multi-drug resistant isolates of Pseudomonas aeruginosa. Against sampled Haemophilus influenzae (39.2% ampicillin-resistant), piperacillin/tazobactam (MIC(90,) < or = 0.06 microg/ml), ceftriaxone and ceftazidime inhibited 100.0% of the isolates at < or = 0.25 microg/ml. These in vitro surveillance results from the year 2000 on three continents, demonstrated a sustained potent activity of piperacillin/tazobactam against selected problematic nosocomial and community-acquired pathogens. The potential importance of these findings is that this beta-lactamase inhibitor combination can be used an empiric treatment of serious infections in hospital environments where resistance has emerged, as well as covering nearly all isolates of fastidious respiratory tract pathogens acquired in the community setting. |
| | |
Authors:
|
David M Johnson; Douglas J Biedenbach; Ronald N Jones |
Related Documents
:
|
10864149 - Anti-leukaemic and anti-mutagenic effects of di(2-ethylhexyl)phthalate isolated from al... 11462189 - A nosocomial outbreak of fluoroquinolone-resistant streptococcus pneumoniae. 17594989 - Marine algae: screening for a potent antibacterial agent. 11086189 - A microcalorimetric method for studying the biological effects of la(3+) on escherichia... 22234269 - Bacteriophages and their implications on future biotechnology: a review. 4670509 - In vitro susceptibility of isolates of aspergillus fumigatus and sporothrix schenckii t... 8708329 - Colonization of streptomycin-treated mice by aeromonas species. 8702269 - Root colonization of maize and lettuce by bioluminescent rhizobium leguminosarum biovar... 6349929 - Bovine rumenitis - liver abscess complex: a bacteriological review. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Diagnostic microbiology and infectious disease Volume: 43 ISSN: 0732-8893 ISO Abbreviation: Diagn. Microbiol. Infect. Dis. Publication Date: 2002 May |
Date Detail:
|
Created Date: 2002-06-07 Completed Date: 2002-08-19 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8305899 Medline TA: Diagn Microbiol Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 49-60 Citation Subset: IM |
Affiliation:
|
JMI Laboratories/The JONES Group, North Liberty, Iowa, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Community-Acquired Infections
/
microbiology* Drug Resistance, Multiple, Bacterial* Drug Therapy, Combination / pharmacology Europe Gram-Negative Bacteria / drug effects*, physiology Gram-Positive Bacteria / drug effects*, physiology Humans Latin America Microbial Sensitivity Tests North America Penicillanic Acid / analogs & derivatives, pharmacology* Piperacillin / pharmacology* Respiratory Tract Infections / microbiology* Sentinel Surveillance Time Factors |
| Chemical | |
Reg. No./Substance:
|
157044-21-8/piperacillin-tazobactam combination product; 61477-96-1/Piperacillin; 87-53-6/Penicillanic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Agar diffusion, agar dilution, Etest, and agar screening test in the detection of methicillin resist...
Next Document: Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.